Romosozumab Treatment in Postmenopausal Women with Osteoporosis

In this RCT (n=7,180) patients received 12 months of romosozumab (RM) or placebo, and then converted to 12 further months of denosumab. At 12 months and 24 months the incidence of vertebral fractures was lower for RM vs placebo (0.5% vs 1.8%, and 0.6% vs 2.5%, p<0.001 for both)

Romosozumab is a humanized monoclonal antibody inhibitor of sclerostin currently under investigation in phase 3 clinical trials for post-menopausal osteoporosis.

 

An editorial discusses the new approach of sequential anabolic therapy investigated in this trial.  It details that the long-term treatment of osteoporosis remains challenging, and romosozumab may be one answer, however more trials are needed before we can embrace a new approach.